Open science and consensus antibody validation protocols can identify high-quality, renewable antibodies for the ~50% of the human proteome currently covered, enabling robust and reproducible biomedical research.

There is an ongoing need for researchers and all stakeholders to better understand issues surrounding antibody characterization to improve the quality and reproducibility of research that employs these reagents.

An easy-to-implement antibody validation pipeline addresses the reproducibility crisis resulting from the use of non-specific antibodies.

Researchers should define in advance the criteria for excluding the results of experiments that 'did not work' from articles.

Variation in SARS-CoV-2 viral kinetics are partly explained by an individual's immune state and the infecting variant, but substantial interpersonal variation limits the reliability of isolation policies tailored to an individual's vaccination status.

A strategy to identify high-quality commercially available antibodies for research reveals extensive use of non-specific antibodies and offers solutions for future large-scale testing.

The absolute affinities of thousands of variant antibodies are measured in parallel using a combination of cell sorting and high-throughput DNA sequencing.

Panproteome array analysis of antibody responses to a pneumococcal whole cell vaccine reveals consistent induction of immune responses to multiple surface proteins, despite individuals' unique pre-existing antibody profiles.

Analysis of Chlamydomonas, planaria and mice reveals a novel and unanticipated role for a peptide amidating enzyme in primary and motile ciliary assembly through effects on post-Golgi trafficking.

By comparing gene expression in people before and after they received the influenza vaccine, researchers were able to identify genes that contribute to differences in individual responses to vaccination.